- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01406483
Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting (Serial CABG)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The recent emergence of platelet reactivity testing as a potential option for evaluating the degree of platelet inhibition promises to add another level of understanding to our concept of CABG-related bleeding. There is an emerging literature that links high levels of platelet reactivity with adverse clinical events, primarily in patients on clopidogrel.
For example, studies of the VerifyNow P2Y12 platelet function assay have shown that Platelet Reactivity Units (PRU) > 235-240 in patients on clopidogrel therapy appears to predict cardiovascular events.15,16 There is a paucity of literature, however, on the use of platelet reactivity testing to predict bleeding events and complications. In other words, if excessively high levels of platelet reactivity predict ischemic events, do excessively low levels of platelet reactivity predict bleeding events? This is an especially relevant question, given the emergence of prasugrel as a therapeutic option.
The investigators therefore propose an exploratory cohort study of patients receiving a thienopyridine (clopidogrel or prasugrel) and undergoing CABG, in order to describe levels of platelet reactivity in such patients by using a variety of platelet function tests.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients ≥ 18 years old from both genders.
- Taking maintenance thienopyridine therapy within 5 days of surgery OR received a loading dose of thienopyridine therapy within 48 hours of surgery for CABG.
- Referred for CABG (which is scheduled to be performed during the current admission).
Exclusion Criteria:
- Known allergies to aspirin, clopidogrel, or prasugrel.
- Use of a glycoprotein (GP) IIb/IIIa inhibitor within 8 hours of initial platelet reactivity testing.
- Patient known to be pregnant or lactating.
- Patient with known history of bleeding diathesis or currently active bleeding.
- Platelet count <100,000/mm the day of initial blood draw.
- Hematocrit <25% the day of initial blood draw.
- On warfarin therapy at the time of initial blood draw.
- Known blood transfusion within the preceding 10 days of the blood draw.
- Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS) within the previous 5 days.
- Plan for patient to be discharged before undergoing CABG.
- Any significant medical condition that, in the investigator's opinion, may interfere with the patient's optimal participation in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: CABG
|
Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Serial levels of platelet reactivity, as assessed with the Chrono-log Lumi-Aggregometer
Tidsram: Duration of hospital stay; average hospital stay of 1 week
|
Serial levels of platelet reactivity, as assessed with the Chrono-log Lumi-Aggregometer, which measures levels of light transmittance after stimulation with ADP to estimate levels of platelet aggregation
|
Duration of hospital stay; average hospital stay of 1 week
|
Perioperative rates of bleeding complications
Tidsram: Duration of hospital stay; average hospital stay of 1 week
|
Perioperative rates of bleeding complications:
|
Duration of hospital stay; average hospital stay of 1 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Serial levels of platelet reactivity, as assessed with the VerifyNow P2Y12 assay
Tidsram: Duration of hospital stay; average hospital stay of 1 week
|
Serial levels of platelet reactivity, as assessed with the VerifyNow P2Y12 assay, which measures platelet reactivity units (PRUs)
|
Duration of hospital stay; average hospital stay of 1 week
|
Serial levels of platelet reactivity, as assessed with the Vasodilator Stimulated Phosphoprotein (VASP) assay
Tidsram: Duration of hospital stay; average hospital stay of 1 week
|
Serial levels of platelet reactivity, as assessed with the Vasodilator Stimulated Phosphoprotein (VASP) assay, which measures percentage of platelet reactivity inhibition (PRI) by flow cytometry of the VASP-P protein
|
Duration of hospital stay; average hospital stay of 1 week
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Serial CABG
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Komplikation av kransartärbypassgraft
-
IRCCS Policlinico S. DonatoRekryteringAnomalous aortic origin of the coronary artery (AAOCA)Italien
Kliniska prövningar på Platelet reactivity assessment
-
Matthew PingreeAktiv, inte rekryterandeLumbal spondylosFörenta staterna
-
Matthew GettmanAvslutad
-
Al-Azhar UniversityRekryteringKaries | Utbrott | Body mass IndexEgypten
-
KLE Society's Institute of Dental SciencesAvslutadRegenerativ inflammationIndien
-
University of California, San DiegoRekrytering
-
Brown UniversityNational Institute on Drug Abuse (NIDA)RekryteringAnvändning av elektronisk cigarett | Rökning, cigarettFörenta staterna
-
German Heart InstituteThe German Heart FoundationOkänd
-
Skin Care and Laser Physicians of Beverly HillsEclipse Aesthetics, LLCOkändAndrogen alopeciFörenta staterna
-
Thomas Jefferson UniversityAvslutadHematopoetisk och lymfoid cellneoplasma | Malign fast neoplasmaFörenta staterna
-
Nantes University HospitalHar inte rekryterat ännuBipolär sjukdom | Beteendevariant av frontotemporal störning (bvFTD) | Fenokopi frontotemporal demens (phFTD) | Frontal variant av Alzheimers sjukdom